Site maintenance Wednesday, November 13th, 2024. Please note that access to some content and account information will be unavailable on this date.
Skip to main content
Full access
Letters to the Editor
Published Online: 12 May 2021

Ubiquitous Dopamine Deficit Hypotheses in Cocaine Use Disorder Lack Support: Response to Leyton

To the Editor: Commenting on the interpretation of results from our study using neuromelanin-sensitive MRI (NM-MRI) in cocaine use disorder (1), Leyton questioned whether we underemphasized evidence of elevated dopamine transmission under certain conditions in addiction. He suggested an alternative explanation for the elevated NM-MRI signal we observed in cocaine use disorder as resulting from increased dopamine transmission. We agree that this and other possible explanations for our data should be evaluated. We had indeed discussed the possibility that elevated NM accumulation could reflect increased dopamine transmission during acute cocaine exposure, and perhaps a similar phenotype could arise from increased cue-induced dopamine signaling as Leyton suggests.
We do, however, caution that the hypothesized model we put forward to situate our findings within the dopamine-imaging literature in cocaine use disorder should not be taken as a general model of addiction or addiction risk. In cocaine use disorder, consistent evidence indicates a blunting of dopamine release—as described in a meta-analysis of positron emission tomography (PET) studies consistently showing that cocaine use disorder is associated with blunted stimulant-induced dopamine release (2). Given this and our previous work showing a positive relationship between NM-MRI signal and dopamine release capacity, we hypothesized a priori that cocaine use disorder would exhibit a decrease in NM-MRI signal. We instead observed a robust increase. Although this result was surprising, we do not believe that this finding challenges the meta-analytical evidence for blunted dopamine release in cocaine use disorder (2). Indeed, upon closer inspection of the literature, we found that the consistent findings of a decrease in vesicular monoamine transporter 2 (VMAT2) in cocaine use disorder (and in nonhuman primates chronically exposed to cocaine) (35) may be readily reconciled with both our finding of decreased NM-MRI signal and the PET findings of blunted dopamine release (because decreased VMAT2 would increase cytosolic dopamine, boosting NM formation [6, 7], and would decrease the vesicular dopamine pool available for release). As discussed in more detail in our article, we consider this biologically plausible scenario as a parsimonious model with the potential to integrate results from several lines of research. This hypothesized model does not, of course, preclude the possibility of increased dopamine signaling in cocaine use disorder under certain conditions or stages of the illness, which in principle could compound a reduction in VMAT2 expression to further augment NM accumulation.
In conclusion, we hypothesized a possible explanation for elevated NM-MRI signal in cocaine use disorder in terms of VMAT2-related changes in dopamine trafficking that warrants empirical testing against alternative hypotheses, for instance, via multimodal studies with NM-MRI and PET measures of dopamine transmission and VMAT2 density. We hope that our work stimulates additional research that can address these critical questions and that NM-MRI contributes new information to achieve an integrated understanding of molecular mechanisms of addiction.

References

1.
Cassidy CM, Carpenter KM, Konova AB, et al : Evidence for dopamine abnormalities in the substantia nigra in cocaine addiction revealed by neuromelanin-sensitive MRI. Am J Psychiatry 2020 ; 177 : 1038 – 1047
2.
Ashok AH, Mizuno Y, Volkow ND, et al : Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis. JAMA Psychiatry 2017 ; 74 : 511 – 519
3.
Little KY, Krolewski DM, Zhang L, et al : Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. Am J Psychiatry 2003 ; 160 : 47 – 55
4.
Narendran R, Jedema HP, Lopresti BJ, et al : Decreased vesicular monoamine transporter type 2 availability in the striatum following chronic cocaine self-administration in nonhuman primates. Biol Psychiatry 2015 ; 77 : 488 – 492
5.
Narendran R, Lopresti BJ, Martinez D, et al : In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers. Am J Psychiatry 2012 ; 169 : 55 – 63
6.
Liang CL, Nelson O, Yazdani U, et al : Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons. J Comp Neurol 2004 ; 473 : 97 – 106
7.
Zucca FA, Basso E, Cupaioli FA, et al : Neuromelanin of the human substantia nigra: an update. Neurotox Res 2014 ; 25 : 13 – 23

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 469 - 470
PubMed: 33979543

History

Accepted: 7 December 2020
Published in print: May 01, 2021
Published online: 12 May 2021

Keywords

  1. Addiction Psychiatry
  2. Substance-Related and Addictive Disorders
  3. Stimulants
  4. Dopamine
  5. Cocaine Use Disorder

Authors

Details

Clifford M. Cassidy, Ph.D. [email protected]
University of Ottawa Institute of Mental Health Research, affiliated with The Royal, Ottawa (Cassidy); Department of Psychiatry, Columbia University College of Physicians and Surgeons, and New York State Psychiatric Institute, New York (Cassidy, Abi-Dargham, Martinez, Horga); Department of Psychiatry, Rutgers University, Piscataway, N.J. (Konova); Department of Psychiatry, Stony Brook University, Stony Brook, N.Y. (Abi-Dargham).
Anna B. Konova, Ph.D.
University of Ottawa Institute of Mental Health Research, affiliated with The Royal, Ottawa (Cassidy); Department of Psychiatry, Columbia University College of Physicians and Surgeons, and New York State Psychiatric Institute, New York (Cassidy, Abi-Dargham, Martinez, Horga); Department of Psychiatry, Rutgers University, Piscataway, N.J. (Konova); Department of Psychiatry, Stony Brook University, Stony Brook, N.Y. (Abi-Dargham).
Anissa Abi-Dargham, M.D.
University of Ottawa Institute of Mental Health Research, affiliated with The Royal, Ottawa (Cassidy); Department of Psychiatry, Columbia University College of Physicians and Surgeons, and New York State Psychiatric Institute, New York (Cassidy, Abi-Dargham, Martinez, Horga); Department of Psychiatry, Rutgers University, Piscataway, N.J. (Konova); Department of Psychiatry, Stony Brook University, Stony Brook, N.Y. (Abi-Dargham).
Diana Martinez, M.D.
University of Ottawa Institute of Mental Health Research, affiliated with The Royal, Ottawa (Cassidy); Department of Psychiatry, Columbia University College of Physicians and Surgeons, and New York State Psychiatric Institute, New York (Cassidy, Abi-Dargham, Martinez, Horga); Department of Psychiatry, Rutgers University, Piscataway, N.J. (Konova); Department of Psychiatry, Stony Brook University, Stony Brook, N.Y. (Abi-Dargham).
Guillermo Horga, M.D., Ph.D.
University of Ottawa Institute of Mental Health Research, affiliated with The Royal, Ottawa (Cassidy); Department of Psychiatry, Columbia University College of Physicians and Surgeons, and New York State Psychiatric Institute, New York (Cassidy, Abi-Dargham, Martinez, Horga); Department of Psychiatry, Rutgers University, Piscataway, N.J. (Konova); Department of Psychiatry, Stony Brook University, Stony Brook, N.Y. (Abi-Dargham).

Notes

Send correspondence to Dr. Cassidy ([email protected]).

Funding Information

The authors’ disclosures accompany the original article.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share